GSK Stock Score & AI Analysis
AI-scored August 18, 2026 · 15-dimension engine · 30+ data sources
GSK scores 29/100 — SELL. Strongest on earnings momentum, weakest on earnings.
Why GSK scores 29
- MACD bearish crossover
- Price below key moving averages
- PEG overvalued (2.61)
Strongest dimension: earnings momentum · Weakest: earnings
GSK balance sheet
NET DEBTCan this company fund itself without the capital markets? Straight from the quarterly filings.
As of the June 30, 2026 balance sheet. Net debt decreasing quarter-over-quarter.
See the full 15-dimension breakdown for GSK
Every component score, the full research report, trade plan, options flow, insider & congressional activity — updated every morning before the bell.
Start Free Trial →GSK — frequently asked
Our AI engine currently rates GSK SELL, with a composite score of 29/100 across 15 dimensions. This is software-generated analysis, not personalized investment advice.
GSK scores 29 out of 100 — in the top 71% of the 1,000+ stocks we screen. The score blends technicals, fundamentals, sentiment, momentum, smart-money flow, options flow, earnings, and insider activity.
Wall Street Analyst reads 30+ live data sources every morning and scores GSK on a 15-dimension engine. The full per-dimension breakdown and research report are available to members.
Wall Street Analyst is financial software and education — not personalized investment advice, and we are not a registered investment advisor. Scores are model-generated and update daily. Markets carry risk; past results don't guarantee future ones, and every decision is yours.